| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it.   |
The Motley Fool
July 25, 2005
Charly Travers |
Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged? |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders. |
The Motley Fool
June 21, 2005
Charly Travers |
A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire. |
InternetNews
August 19, 2005
Roy Mark |
Secure Computing to Acquire CyberGuard The $295 million deal will combine market leaders in the application proxy firewall space. Secure Computing will issue CyberGuard stockholders cash and stock in return for their shares. |
The Motley Fool
February 24, 2005
Charly Travers |
Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value. |
The Motley Fool
July 25, 2011
Travis Hoium |
Bridgepoint Education Shares Plunged: What You Need to Know Investors in postsecondary education provider Bridgepoint Education had a rude awakening this morning when shares fell 12% to start the week. |
The Motley Fool
May 12, 2005
Tom Taulli |
ScanSoft's Nuanced Deal Wall Street doesn't like ScanSoft's merger with Nuance. But private equity firm Warburg Pincus does. |
The Motley Fool
May 17, 2007
Matt Koppenheffer |
Bausch & Lomb: How Much Is Too Much? Private equity's Warburg Pincus agrees to take the eye-care company private. Investors, take note. |
The Motley Fool
May 1, 2006
Rich Duprey |
Searching for Profits in R&D: Part 1 Here's why treating R&D as an investment can lead you to some up-and-coming small caps worthy of your investment dollars. |
InternetNews
November 11, 2004
Colin C. Haley |
Report: Telecordia to be Bought for $1.3B The telecom software maker is reportedly close to being sold to two private-equity firms. |
The Motley Fool
October 7, 2004
Seth Jayson |
Painless? My Assets Another warning from dental tech firm Biolase Technology sends the stock down. |
The Motley Fool
August 9, 2005
Seth Jayson |
The Investor's Frame of Mind Curiosity is the successful investor's prime attribute. |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
U.S. Banker
June 2007
Lee Conrad |
M&A: Private Equity Takes Aim At Financial-IT Vendors Financial-IT companies are expected to lure a growing number of private-equity investors over the next few years. |
The Motley Fool
November 22, 2005
Emmet Savage |
Think Small, Think Great Tomorrow's blue chips are today's small fries. With a Level 5 leader at its helm, it could be tomorrow's next big stock. The trick is to find it today. |
InternetNews
February 10, 2005
Jim Wagner |
ICANN's .Net Evaluator Under Scope ICANN's independent evaluator has some history with two of the companies looking to assume control of the domain extension. |
